EcoDrugPlus

Atpase Na+/k+ Transporting Subunit Alpha 4

Ensembl ID : ENSBMSG00010004094
Gene Symbol: ATP1A4
1 Cross references
571 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Beta 1

Ensembl ID : ENSBMSG00010008937
Gene Symbol: ATP1B1
1 Cross references
290 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Beta 2

Ensembl ID : ENSBMSG00010015043
Gene Symbol: ATP1B2
1 Cross references
269 Possible Orthologues:

Atr Serine/threonine Kinase

Ensembl ID : ENSBMSG00010002907
Gene Symbol: ATR
1 Cross references
207 Possible Orthologues:

Axl Receptor Tyrosine Kinase

Ensembl ID : ENSBMSG00010017808
Gene Symbol: AXL
1 Cross references
198 Possible Orthologues:

B-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSBMSG00010014913
Gene Symbol: BRAF
1 Cross references
220 Possible Orthologues:

Bcl2 Apoptosis Regulator

Ensembl ID : ENSBMSG00010012548
Gene Symbol: BCL2
1 Cross references
228 Possible Orthologues:

Bcl2 Like 1

Ensembl ID : ENSBMSG00010012432
Gene Symbol: BCL2L1
1 Cross references
289 Possible Orthologues:

Bcl2 Like 2

Ensembl ID : ENSBMSG00010011083
Gene Symbol: BCL2L2
1 Cross references
64 Possible Orthologues:

Bcl2 Related Protein A1

Ensembl ID : ENSBMSG00010007836
Gene Symbol: BCL2A1
1 Cross references
133 Possible Orthologues:

Bcr Activator Of Rhogef And Gtpase

Ensembl ID : ENSBMSG00010017827
Gene Symbol: BCR
1 Cross references
286 Possible Orthologues:

Bruton Tyrosine Kinase

Ensembl ID : ENSBMSG00010019923
Gene Symbol: BTK
1 Cross references
207 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).